Generalized Myasthenia Gravis (GMG) Management MarketThe global Generalized Myasthenia Gravis (GMG) Management Market is projected to poise a robust growth rate by exhibiting a compound annual growth rate (CAGR) of 7.6% from 2023 to 2033. The global market size is expected to surpass an impressive valuation of US$ 1.
FDA approval of UCB’s Bimzelx gives the Belgian drugmaker a contender in the crowded plaque psoriasis therapies market. In the rare disease generalized myasthenia gravis, the agency approved Zilbrysq, a UCB drug with advantages over two blockbuster AstraZeneca drugs addressing the same target.
Qualitative interviews were conducted and a web-based quantitative survey was administered to have a clearer understanding of the economic impact of social determinants of health on patients living with generalized myasthenia gravis (gMG).
Patients with generalized myasthenia gravis treated with efgartigimod consistently exceeded treatment compared with placebo regardless of gender in age, disease duration, body mass index, and thymectomy.